Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 6/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.39 |
| ▸ | CDK2 | P24941 | 2/20 | 0.39 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.39 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.39 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.36 |
| ▸ | MAPKAPK5 | Q8IW41 | 3/20 | 0.36 |
| ▸ | FLT3 | P36888 | 2/20 | 0.35 |
| ▸ | LCK | P06239 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | FYN | P06241 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14529900 | 0.90 | TTK (0.50) | TTKAURKAAURKBMAPKAPK5FLT3 | |
| SCHEMBL15146186 | 0.83 | FYN (0.49) | TTKAURKAAURKBMAPKAPK5FLT3 | |
| SCHEMBL14530729 | 0.80 | AURKA (0.51) | TTKAURKAAURKBMAPKAPK5FYN | |
| SCHEMBL14530725 | 0.79 | ABL1 (0.40) | TTKAURKAAURKBLCK | |
| SCHEMBL14537080 | 0.79 | AURKA (0.45) | TTKAURKAAURKBMAPKAPK5FLT3 | |
| SCHEMBL8247128 | 0.78 | AURKA (0.63) | TTKAURKAMAP4K4CCNA2CDK2 | |
| SCHEMBL14387671 | 0.77 | MAPKAPK5 (0.41) | TTKAURKAMAP4K4CCNA2CDK2 | |
| SCHEMBL14507243 | 0.77 | EGFR (0.41) | TTKAURKAAURKBMAPKAPK5FLT3 | |
| SCHEMBL14530155 | 0.75 | AURKA (0.43) | TTKAURKAAURKBMAPKAPK5FLT3 | |
| SCHEMBL14536961 | 0.72 | FLT3 (0.51) | TTKFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070105864-A1 | Methods for inhibiting protein kinases | SCHERING CORPORATION | 2007-05-10 | — | — | US | disclosed |
| US-20070105864-A1 | Methods for inhibiting protein kinases | SCHERING CORPORATION | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105864-A1 | Methods for inhibiting protein kinases | PIM1, PIM2, PIM3 | TTK 69/4885AURKA 5/4885MAP4K4 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.